Timothy Juday, PhD, MPA

Lemborexant and suvorexant for treating insomnia: An indirect comparison using number needed to treat, number needed to harm, and likelihood to be helped or harmed

Introduction: Lemborexant is approved in the US for treating insomnia in adults. We evaluated the evidence-base for lemborexant and suvorexant, both dual orexin receptor antagonists (DORA...

Timothy Juday , PhD, MPA;

Norman Atkins Jr., MBA, PhD;

Feride Frech , PhD, MPH;

Leslie Citrome , MD;

Manoj Malhotra , MD;

10/08/2020

Incremental Healthcare Costs of Insomnia Among Adult Patients With Alzheimer’s Disease or Related Dementias in the United States

Abstract: Background: Insomnia contributes to cognitive decline, increased fall risk, and nursing home placement in patients with Alzheimer’s disease and related dementias (ADRD). Obje...

Timothy Juday , PhD, MPA;

01/19/2023

Burden of Insomnia in Patients Undergoing Cancer Treatment: A US Retrospective Claims Database Analysis

Abstract: Almost half of patients with cancer have trouble sleeping and treatment can exacerbate these problems. Objectives: This study evaluated healthcare resource utilization (HCRU) a...

Timothy Juday , PhD, MPA;

01/19/2023

Lemborexant and Daridorexant for the Treatment of Insomnia: An indirect comparison, using number needed to treat, number needed to harm, and likelihood to be helped or harmed

Background: To describe lemborexant and daridorexant for insomnia treatment using number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH). ...

Timothy Juday , PhD, MPA;

01/19/2023

Incremental Economic Burden Associated with Insomnia Among Patients with Type 2 Diabetes in the United States: A Retrospective Claims Database Analysis

Abstract: Background: While insomnia occurs in half of adults with type 2 diabetes (T2D), its incremental economic impact in this population is unclear.

Timothy Juday , PhD, MPA;

01/19/2023